Transplantation Characteristics of Patients With Secondary AML Based on Pretransplant Therapy for AML
| . | Preceding Induction Chemotherapy* . | |
|---|---|---|
| . | No . | Yes . |
| Stem cell source† number | ||
| Identical twin | 3 | 0 |
| Genotypically HLA identical sibling | 27 | 14 |
| Phenotypically HLA-A, B, Dw/DRB1 matched family member | 2 | 0 |
| 1 HLA-A, B, DR mismatched family member‡ | 4 | 1 |
| HLA-A, B, Dw/DRB1 matched unrelated donor | 8 | 3 |
| 1 “minor” HLA locus mismatched unrelated donorρ | 2 | 2 |
| Preparative regimen | ||
| Chemotherapy only2-155 | 12 | 5 |
| Cyclophosphamide-TBI2-154 | 22 | 15 |
| Busulfan (or dimethylmyleran)-cyclophosphamide-TBI2-167 | 12 | 0 |
| GVHD prophylaxis | ||
| None | 3 | 0 |
| Methotrexate only | 7 | 2 |
| Cyclosporine only | 3 | 2 |
| Cyclosporine and methotrexate | 21 | 14 |
| Cyclosporine and corticosteroids | 7 | 1 |
| Cyclosporine and FK506 | 5 | 1 |
| . | Preceding Induction Chemotherapy* . | |
|---|---|---|
| . | No . | Yes . |
| Stem cell source† number | ||
| Identical twin | 3 | 0 |
| Genotypically HLA identical sibling | 27 | 14 |
| Phenotypically HLA-A, B, Dw/DRB1 matched family member | 2 | 0 |
| 1 HLA-A, B, DR mismatched family member‡ | 4 | 1 |
| HLA-A, B, Dw/DRB1 matched unrelated donor | 8 | 3 |
| 1 “minor” HLA locus mismatched unrelated donorρ | 2 | 2 |
| Preparative regimen | ||
| Chemotherapy only2-155 | 12 | 5 |
| Cyclophosphamide-TBI2-154 | 22 | 15 |
| Busulfan (or dimethylmyleran)-cyclophosphamide-TBI2-167 | 12 | 0 |
| GVHD prophylaxis | ||
| None | 3 | 0 |
| Methotrexate only | 7 | 2 |
| Cyclosporine only | 3 | 2 |
| Cyclosporine and methotrexate | 21 | 14 |
| Cyclosporine and corticosteroids | 7 | 1 |
| Cyclosporine and FK506 | 5 | 1 |
Abbreviation: TBI, total body irradiation.
Induction chemotherapy use as treatment for secondary AML before transplantation.
Non T-cell depleted marrow was used in 65 cases. Growth factor mobilized PB stem cells were used in 1 case.
Mismatched at A locus in 1 case, B locus in 1 case, and DR locus in 3 cases.
ρ “Minor” mismatch was defined as a single HLA mismatch for a pair of DRB1 alleles belonging to the same DR type (DR1-18) (3 cases) or for a pair of HLA-A or B antigens within a cross-reactive group (1 case).
Cyclophosphamide-busulfan (15 cases), cyclophosphamide only (1 case), carmustine-cyclophosphamide-etoposide (1 case).
10 Gy (1 case), 12 Gy (8 cases), 13.2 Gy (13 cases), 14.4 Gy (3 cases), 15.75 Gy (12 cases).
Busulfan (11 cases), dimethylmyleran (1 case).